NEW YORK (GenomeWeb News) - Caliper Life Sciences today reported preliminary fourth-quarter revenue of approximately $36 million and preliminary full-year revenue of $123.5 million.
The preliminary results reflect a 4 percent dip from $37.7 million in the fourth quarter of 2009 and a 5 percent decrease in annual revenues compared to 2009. The company said that organic revenues grew 10 percent year-over-year.
The results beat the upper end of the company's previous revenue guidance for full-year 2010 of between $119 million and $121 million.
Caliper said that it also expects to report positive non-GAAP earnings per share for the fourth quarter and on a full-year basis for 2010, but did not provide further details.
The company expects to report cash, cash equivalents, and marketable securities of approximately $35 million as of Dec. 31, 2010, and positive operating cash flows of between $3.5 million and $4 million within the fourth quarter and on a full-year basis.
The company also disclosed that Seegene has ordered 17 of its newly launched Labchip Dx systems, valued at more than $500,000, which will be shipped over the next three months to customers in six countries. Yesterday, the companies announced a partnership under which Seegene's SeePlex multiplex diagnostic assays will run on the LabChip Dx platform.
Caliper said that it expects total revenue for 2011 to increase between 12 percent and 20 percent over non-GAAP revenues of approximately $120 million for fiscal 2010. That increase would represent an improvement of between 8 percent and 16 percent over projected GAAP revenues of $123.5 million.